A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL

Enrollment

231

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

September 21, 2021

Study Completion Date

September 21, 2021

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

DRUG

Placebo

DRUG

Prothione™ (6g)

Prothione is a pro-Glutathione compound includes free-form amino acids

Trial Locations (1)

Rinda Ubuzima, Kigali

All Listed Sponsors

lead

Prothione, LLC

OTHER